Vanda Pharmaceuticals Inc
VNDA
Market Cap$232.79M
Close$
$10.13
156.4% upside
Current Fair Value
156.4% upsideUndervalued by 156.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $232.79 Million |
|---|---|
| Enterprise Value | $142.83 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.33 |
| Beta | 0.69 |
| Outstanding Shares | 58,308,487 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -12.19 |
|---|---|
| PEG | 0.31 |
| Price to Sales | 1.32 |
| Price to Book Ratio | 0.44 |
| Enterprise Value to Revenue | 0.75 |
| Enterprise Value to EBIT | -3.81 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Vanda Pharmaceuticals Inc
CEO: Mihael Polymeropoulos Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.